Advertisement
Advertisement
Skip to content
Follow Us on
Advertisement
TOP STORIES
Business

Biocon receives EU approval for pertuzumab biosimilar under new clinical approach

Advertisement

Biocon Limited, a global biopharmaceutical company headquartered in Bengaluru, has announced that the European Commission (EC) has granted marketing authorisation for Pebrilzo®, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer in the European Union. This approval marks a significant milestone as it is the first biosimilar to be approved under the European Medicines Agency’s new tailored clinical approach.

The approval of Pebrilzo® follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in September 2026 and comes on the heels of recent U.S. FDA approval. Biocon’s pertuzumab biosimilar is intended to broaden treatment options for patients with HER2-positive breast cancer while promoting sustainable healthcare systems across Europe. Shreehas Tambe, CEO & Managing Director of Biocon, highlighted the significance of this approval in strengthening the company’s oncology portfolio and reaffirming its commitment to providing high-quality, affordable biologic therapies.

Biocon’s pertuzumab biosimilar is indicated for use in combination with trastuzumab and chemotherapy for adult patients with HER2-positive breast cancer, including those with locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence, as well as for metastatic or locally recurrent unresectable breast cancer. The biosimilar has undergone extensive structural and functional analytical characterisation, demonstrating high similarity to the reference product with no clinically meaningful differences in quality, safety, or efficacy.

The approval of Pebrilzo® further solidifies Biocon’s position in the oncology sector, where it has been actively expanding its portfolio to address various aspects of cancer care. Breast cancer remains the most commonly diagnosed cancer among women in Europe, with approximately 15–20% of invasive cases characterised by HER2 overexpression. The availability of Biocon’s biosimilar pertuzumab is expected to play a crucial role in enhancing access to effective treatment options for patients across European healthcare systems.

Market analysts view Biocon’s latest achievement as a strategic advancement in the competitive biosimilars market, potentially enhancing the company’s market share in oncology therapeutics. The approval underscores Biocon’s commitment to addressing unmet medical needs and its capability to innovate within the regulatory frameworks of major global markets.

Advertisement

Join TaxGuru's Network for the latest updates on Income Tax, GST, Company Law, Corporate Laws and other related subjects.

Leave a Reply

Your email address will not be published. Required fields are marked *